GlassScriptPhysician profile
Robert Shannon Moran
NPI 1558604132
$3,181.92
in general payments reported to CMS, 2019-2025
29 companies · $581 in 2025
The $581 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $392 · 2021: $511 · 2022: $642 · 2023: $382 · 2024: $455 · 2025: $581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,418.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,417.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $625.77 | 2019-2025 | Bexsero, Shingrix |
| Corium, LLC | $511.05 | 2022-2025 | Azstarys, Azstarys |
| Supernus Pharmaceuticals, INC. | $253.10 | 2021-2025 | Qelbree |
| Tris Pharma INC | $244.61 | 2020-2025 | Dyanavel Xr |
| Pfizer INC. | $198.54 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $184.87 | 2019-2025 | Vaxelis, Gardasil 9, Vaxneuvance |
| Ironshore Pharmaceuticals INC. | $178.79 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $153.16 | 2021-2025 | Elaprase |
| Kaleo, INC. | $121.42 | 2019-2021 | |
| Neos Therapeutics, LP | $111.69 | 2020-2021 | |
| Adlon Therapeutics L.P. | $72.00 | 2021 | |
| Collegium Pharmaceutical, INC. | $62.12 | 2025 | Jornay Pm |
| Sobi, INC | $57.29 | 2020-2023 | |
| Verrica Pharmaceuticals INC. | $48.15 | 2024 | Ycanth |
| Sanofi-Aventis U.S. LLC | $42.58 | 2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $39.01 | 2021 | |
| Genentech USA, INC. | $38.35 | 2019-2020 | |
| Cranial Technologies, INC | $30.17 | 2020-2025 | Doc Band |
| Genzyme Corporation | $25.99 | 2023 | |
| Seqirus USA INC | $25.19 | 2023 | Flucelvax Quadrivalent |
| Ascendis Pharma Endocrinology INC | $23.57 | 2024 | |
| Noven Therapeutics, LLC | $21.02 | 2024 | Secuado, Xelstrym |
| Biomarin Pharmaceutical INC. | $20.26 | 2024 | Voxzogo 1.2mg |
| Sun Pharmaceutical Industries INC. | $18.44 | 2020 | |
| Lnhc, INC | $18.01 | 2025 | Zelsuvmi |
| Phadia US INC. | $15.49 | 2024 | Immunocap |
| Neurelis, INC. | $14.65 | 2023 | Valtoco |
| Qiagen, LLC | $13.82 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $12.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Moran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.